LAG3 / IL-2 Reporter - Jurkat Recombinant Cell Line
Catalog #
79813
$11,095*
●
Purchase
●
Description
Recombinant Jurkat T cell expressing firefly luciferase gene under the control of IL-2 response promoter with constitutive expression of human LAG3 (lymphocyte-activation gene 3, CD223, GenBank Accession # NM_002286).
Assay Principle
Interested in screening and profiling inhibitors, blocking antibodies, or activators of LAG3 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
●
Synonyms
LAG3, LAG-3, CD223, Cell Line, Jurkat
●
Product Data Gallery
Characterization of biological activity of anti-LAG3 neutralizing antibody in LAG3 cell-based assay using the LAG3/IL-2 Reporter-Jurkat cells co-cultured with TCR activator-Raji cells
Characterization of biological activity of anti-MHC class II antibody in LAG3 cell-based assay using the LAG3/IL-2 Reporter-Jurkat cells co-cultured with TCR activator-Raji cells
Characterization of biological activity of anti-MHC class II antibody and anti-LAG3 antibody in cell-based assay using the LAG3/IL-2 Reporter-Jurkat cells or IL-2 reporter-Jurkat cells co-cultured with TCR activator-Raji cells
FACS analysis of cell surface expression of LAG3 in LAG3/IL-2 Reporter-Jurkat cells
The cell line has been screened using the luminescence-based Lonza MycoAlertTM Mycoplasma Detection Kit (Lonza, USA Catalog #: LT07-318) to confirm the absence of Mycoplasma species.
Background
Lymphocyte-activation gene 3 (LAG3, CD223) is a cell surface protein that belongs to the immunoglobulin (Ig) superfamily. LAG3 is expressed on activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. Its main ligand is MHC class II, to which it binds with higher affinity than CD4. It negatively regulates cellular proliferation, activation, and homeostasis of T cells in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. A number of LAG3 antibodies are in preclinical development for treatments for cancer and autoimmune disorders. LAG3 may be a better immune checkpoint inhibitor target than CTLA-4 or PD-1 since antibodies to these two checkpoints are only activating effector T cells, and not inhibiting Treg activity while an antagonist LAG3 antibody can both activate effector T cells (by downregulating the LAG3 inhibiting signal) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.
Storage/Stability
Immediately upon receipt, store in liquid nitrogen.
Culture Conditions
For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.
Growth Medium 2J (BPS Bioscience #79812): RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 500 μg/ml of Geneticin and 1 μg/ml of Puromycin Dihydrochloride
Applications
• Screen for compound activity on LAG3 signaling in a cellular context. • Characterize the biological activity of LAG3 and its interactions with ligands.
Shipping Temperature
-80°C
Notes
License Disclosure Visit bpsbioscience.com/license for the label license and other key information about this product.
Powered by Bioz
